Mutaflor Mite (Escherichia Coli Strain Nissle 1917)

Escherichia coli Nissle 1917, the active ingredient in Mutaflor Mite, is a probiotic / live biotherapeutic presented as a lyophilised oral preparation for oral use. It is employed to support gastrointestinal health in conditions such as ulcerative colitis, inflammatory bowel disease and irritable bowel syndrome.

GNH USA supplies Mutaflor Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mutaflor Mite is a probiotic that acts on the gastrointestinal tract to help manage inflammatory and functional bowel disorders. - Ulcerative colitis: assists in maintaining remission and reducing flare‑ups. - Inflammatory bowel disease: contributes to symptom control and mucosal barrier support. - Irritable bowel syndrome: may improve abdominal comfort and bowel regularity.

Adverse reactions are generally mild and related to gastrointestinal tolerance.

Common Side Effects: - Bloating: transient abdominal distension. - Flatulence: increased gas production. - Abdominal discomfort: mild cramping or pain. - Mild diarrhoea: loose stools that resolve spontaneously. - Nausea: occasional feeling of queasiness. - Headache: low‑grade headache reported by some users.

Serious or Rare Side Effects: - Sepsis: systemic infection, primarily in severely immunocompromised patients. - Bacteremia: presence of the strain in the bloodstream. - Severe allergic reaction: anaphylaxis or angioedema. - Persistent high‑grade fever: may indicate infection. - Gastrointestinal perforation: extremely rare but serious event.

Patients and prescribers should consider several safety measures before initiating therapy. - Immune status assessment: evaluate for severe immunodeficiency before use. - Antibiotic co‑administration: avoid concurrent broad‑spectrum antibiotics that may eradicate the probiotic. - Infection monitoring: watch for signs of systemic infection, especially in vulnerable individuals. - Pregnancy and lactation: use only if the benefit outweighs potential risk, as data are limited. - Medical supervision: ensure therapy is overseen by a qualified healthcare professional. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Probiotic therapy can be influenced by other medications and biologics.

Major Interactions (Avoid): - Broad‑spectrum antibiotics: may significantly reduce the viability of the probiotic strain. - Potent immunosuppressants: increase the risk of systemic infection from the live organism.

Moderate Interactions (Monitor Closely): - Other oral probiotics: concurrent use may alter colonisation dynamics. - Antifungal agents: could affect gut microbial balance and probiotic efficacy. - Live vaccines: consider timing to avoid potential interference with immune response.